These observations raise two interesting questions: (1) whether NG2 may be potential therapeutic target for thyroid cancers, especially particularly those with BRAF mutations; (2) whether NG2 is involved in the resistance of BRAF-mutant thyroid cancers to BRAF inhibitors. The gene discussed is BRAF; the disease is thyroid gland carcinoma.